Literature DB >> 31749055

ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.

Hitoshi Hirakawa1, Taro Ikegami2, Satoe Azechi3, Shinya Agena2, Jin Uezato2, Hidetoshi Kinjyo2, Yukashi Yamashita2, Katsunori Tanaka2, Shunsuke Kondo2, Hiroyuki Maeda2, Mikio Suzuki2, Akira Gahana2,4.   

Abstract

PURPOSE: To evaluate the prognostic significance of DNA excision repair gene polymorphisms, excision repair cross-complementation group 1 (ERCC1) and X-ray repair complementing defective repair in Chinese hamster cells 1 (XRCC1) polymorphisms were investigated in Japanese patients with head and neck squamous cell carcinoma (HNSCC).
METHODS: A total of 225 consecutive patients with HNSCC who underwent surgery or chemoradiotherapy/radiotherapy (CRT/RT) with curative intent as primary treatment from 2006 to 2017 were recruited. ERCC1 C8092A and XRCC1 Arg399Gln polymorphisms in DNA extracted from individual blood samples were determined by the polymerase chain reaction-restriction fragment length polymorphism method. Cumulative survival was estimated by Kaplan-Meier analysis with a log-rank test and Cox proportional hazards model stratified by treatment arm, adjusting for clinical prognostic factors.
RESULTS: Multivariate analysis showed that carriers with the ERCC1 8092 (C/A+A/A) genotype (hazard ratio, 3.56; 95% confidence interval, 1.22-7.39; p = 0.02) had significantly worse survival than those with ERCC1 8092 C/C who received CRT/RT. Conversely, the XRCC1 Arg399Gln polymorphism did not influence survival in patients who received CRT/RT as well as surgery.
CONCLUSION: The ERCC1 C8092A polymorphism might be an independent predictor of response to CRT and survival outcome in patients with HNSCC. This is the first report to investigate the role of DNA excision repair gene polymorphisms in patients with head and neck cancer in a Japanese population.

Entities:  

Keywords:  DNA repair; Head and neck cancer; Japanese; Single nucleotide polymorphism; Survival

Mesh:

Substances:

Year:  2019        PMID: 31749055     DOI: 10.1007/s00405-019-05731-y

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  40 in total

Review 1.  Polymorphisms in DNA repair genes and associations with cancer risk.

Authors:  Ellen L Goode; Cornelia M Ulrich; John D Potter
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-12       Impact factor: 4.254

2.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

Authors:  Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

3.  Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.

Authors:  Y W Ding; X Gao; D X Ye; W Liu; L Wu; H Y Sun
Journal:  Clin Transl Oncol       Date:  2015-05-29       Impact factor: 3.405

4.  Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck.

Authors:  Lie Cheng; Erich M Sturgis; Susan A Eicher; Margaret R Spitz; Qingyi Wei
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

Review 5.  Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases.

Authors:  Sonia S Lin; Sean T Massa; Mark A Varvares
Journal:  Head Neck       Date:  2015-05-25       Impact factor: 3.147

6.  Single nucleotide polymorphisms in nucleotide excision repair genes, cancer treatment, and head and neck cancer survival.

Authors:  Annah B Wyss; Mark C Weissler; Christy L Avery; Amy H Herring; Jeannette T Bensen; Jill S Barnholtz-Sloan; William K Funkhouser; Andrew F Olshan
Journal:  Cancer Causes Control       Date:  2014-02-02       Impact factor: 2.506

Review 7.  Genetic polymorphisms and head and neck cancer risk (Review).

Authors:  Toru Hiyama; Masaharu Yoshihara; Shinji Tanaka; Kazuaki Chayama
Journal:  Int J Oncol       Date:  2008-05       Impact factor: 5.650

8.  Neoadjuvant chemotherapy or chemoradiotherapy in head and neck cancer.

Authors:  Preetesh Jain; Prabhash Kumar; Vasanth Raghuvir Pai; Purvish Mahendra Parikh
Journal:  Indian J Cancer       Date:  2008 Jul-Sep       Impact factor: 1.224

9.  DNA repair gene XRCC1 polymorphisms and head and neck cancer risk: an updated meta-analysis including 16344 subjects.

Authors:  Yin Lou; Wen-jia Peng; Dong-sheng Cao; Juan Xie; Hong-hong Li; Zheng-xuan Jiang
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

10.  DNA repair gene ERCC1 C118T polymorphism predicts sensitivity of recurrent esophageal cancer to radiochemotherapy in a Chinese population.

Authors:  Xian Yu; He Xiao; Baojian Zhao; Xu Zhang; Ge Wang
Journal:  Thorac Cancer       Date:  2015-03-23       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.